Abstract
This new management report covers 30 leading compounds and is essential
reading for everyone working in the field.
After years of anticipation and encouraging responses to pathfinder
products, monoclonal antibodies are now set to realise their true clinical and
commercial potential. But what are the prospects for the products that will
lead the market?
The position of monoclonal antibodies on the market is solidly poised for
growth with six novel therapies expected to launch within the next five years.
The ability to be an effective medicine puts antibodies, and the companies
having a hand in their development, into a position to create new markets.
Buoyed by ticilimumab and ipilimumab, the treatment of melanoma will be among
the first to follow the current blockbuster successes in breast cancer and
leukaemia. Companies with pipelines to sell or in development, such as Genmab,
Immunomedics and Seattle Genetics, have attracted capital from large
pharmaceutical companies and investors.
HUGE POTENTIAL
While large pharma companies predictably take aim at the largest treatable
populations (breast cancer, colorectal disease, NHL, leukaemia), there is an
abundance of niches for monoclonal antibody therapy applications and a
staggering number of potential disease targets. Smaller developer companies
are likely to become more visible as their products move closer to regulatory
approval.
That is why this new management report is essential for everyone working in
the field. The report covers over 30 leading compounds originating from the
largest blue-chip multinationals to smaller developer companies.
KEY EVALUATION FOR EACH PRODUCT
It is vital that new compounds can be seen in the wider
competitive/development landscape. For that reason we have established a
unique competitor analysis based on each of the following criteria:
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with developing a drug within a therapeutic class
View Cart
